AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat '26 View

Key Takeaways ABBV posted Q4 adjusted EPS of $2.71 and revenues of $16.62B, both beating consensus estimates.AbbVie saw strong growth from Skyrizi and Rinvoq, while Humira and Imbruvica sales declined year over year.ABBV guided 2026 adjusted EPS of $14.37-$14.57, excluding impacts from proposed acquisitions.AbbVie Inc. (ABBV) reported fourth-quarter 2025 adjusted EPS of $2.71, which beat the Zacks Consensus Estimate of $2.66. The reported figure also exceeded the company’s guidance of $2.61-$2.65 issued las ...